Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Next-generation biomimetic vesicles for combating antimicrobial resistance in chronic biofilm infections

Objetivo

ARMOR addresses a major challenge in modern medicine: chronic biofilm-associated infections, which are highly resistant to antibiotics and closely linked to antimicrobial resistance. The project will develop a new generation of safe, biomimetic nanovesicles inspired by bacterial outer membrane vesicles that can penetrate biofilms and deliver therapeutics directly to the infection site. By combining detoxified bacterial membrane components with synthetic lipids and responsive materials, ARMOR aims to create programmable vesicles that release their cargo only under biofilm-specific conditions such as acidic pH or bacterial enzymes. The platform will integrate multiple antimicrobial strategies, including antibiotics, antimicrobial peptides, enzymes, and light- and ultrasound-activated agents, to achieve targeted and synergistic biofilm eradication. A distinctive feature of ARMOR is its closed design-build-test-learn framework, in which artificial intelligence, advanced imaging, and quantitative in vitro and in vivo data are combined to iteratively optimise vesicle design, delivery, efficacy, and safety. The project brings together an international, interdisciplinary, and intersectoral consortium spanning academia and industry across Europe and beyond. Through structured staff secondments, shared training, and joint research activities, ARMOR will promote deep transfer of knowledge and build durable collaboration networks. ARMOR is expected to deliver validated preclinical lead formulations, AI-enabled optimisation workflows, and scalable approaches for vesicle production, stabilisation, and quality control. In the longer term, the project will strengthen Europe’s capacity to develop precision anti-infective therapies, reduce reliance on conventional antibiotics, and improve the management of chronic biofilm infections and antimicrobial resistance.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff Exchanges

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-MSCA-2026-SE-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Aportación neta de la UEn
€ 320 540,00
Coste total
Sin datos

Participantes (8)

Socios (5)